Since adoption of the IRA, the Trump Administration has taken a number of actions to reduce the costs of pharmaceutical products, including through the issuance of Executive Orders. For example, a number of pharmaceutical companies have entered into agreements with the Administration to provide for lower prices on certain pharmaceuticals in response to an Executive Order relating to the potential imposition of most favored nation pricing in the United States.
